Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes

References

• Santini V First-line therapeutic strategies for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S31–S36. PubMed PMID: 28760300; eng
   PubMedGoogle Scholar
• Ades L, Itzykson R, Fenaux P Myelodysplastic syndromes. Lancet. 2014 Jun 28;383(9936):2239–2252. PubMed PMID: 24656536; eng.
   PubMed Web of Science ®Google Scholar
• Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007 Nov;31(11):1461–1468. PubMed PMID: 17507091; eng.
   PubMed Web of Science ®Google Scholar
• Bennett JM Changes in the updated 2016: WHO classification of the myelodysplastic syndromes and related myeloid neoplasms. Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):607–609. PubMed PMID: 27693133; eng
   PubMed Web of Science ®Google Scholar
• Gurney M, Patnaik MM, Hanson CA, et al. The 2016 revised World Health Organization definition of ‘myelodysplastic syndrome with isolated del(5q)’; prognostic implications of single versus double cytogenetic abnormalities. Br J Haematol. 2017 Jul;178(1):57–60. PubMed PMID: 28419466; eng.
   PubMed Web of Science ®Google Scholar
• Jonas BA, Greenberg PL MDS prognostic scoring systems - past, present, and future. Best Pract Res Clin Haematol. 2015 Mar;28(1):3–13. PubMed PMID: 25659725; PubMed Central PMCID: PMC4324398. eng.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079–2088. PubMed PMID: 9058730; eng.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454–2465. PubMed PMID: 22740453; PubMed Central PMCID: PMC4425443. eng
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Jul;29(7):1502–1513. PubMed PMID: 25721895; eng.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007 Aug 10;25(23):3503–3510. PubMed PMID: 17687155; eng.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 Sep 11;478(7367):64–69. PubMed PMID: 21909114; eng.
   PubMed Web of Science ®Google Scholar
• Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011 Dec 11;44(1):53–57. PubMed PMID: 22158538; PubMed Central PMCID: PMC3247063. eng.
   PubMed Web of Science ®Google Scholar
• Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012 Apr 5;119(14):3211–3218. PubMed PMID: 22343920; eng.
   PubMed Web of Science ®Google Scholar
• Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012 Apr 5;119(14):3203–3210. PubMed PMID: 22323480; PubMed Central PMCID: PMC3321850. eng.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013 Nov 21;122(22):3616–3627; quiz 3699. PubMed PMID: 24030381; PubMed Central PMCID: PMC3837510. eng.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009 May 28;360(22):2289–2301. PubMed PMID: 19474426; eng.
   PubMed Web of Science ®Google Scholar
• Cazzola M IDH1 and IDH2 mutations in myeloid neoplasms–novel paradigms and clinical implications. Haematologica. 2010 Oct;95(10):1623–1627. PubMed PMID: 20884716; PubMed Central PMCID: PMC2948084. eng.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30;364(26):2496–2506. PubMed PMID: 21714648; PubMed Central PMCID: PMC3159042. eng.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20;30(27):3376–3382. PubMed PMID: 22869879; PubMed Central PMCID: PMC3438234. eng.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011 Jul;25(7):1153–1158. PubMed PMID: 21415852; PubMed Central PMCID: PMC3202965. eng.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011 Jan 18;19(1):17–30. PubMed PMID: 21251613; PubMed Central PMCID: PMC3229304. eng.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015 Jan;29(1):66–75. PubMed PMID: 24935723; eng.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 Jul 15;104(2):579–585. PubMed PMID: 15039286; eng
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Jackson CH, Alessandrino EP, et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017 Apr 7. DOI:10.1038/leu.2017.88. PubMed PMID: 28321120; eng.
   PubMed Web of Science ®Google Scholar
• Shapira MY, Tsirigotis P, Resnick IB, et al. Allogeneic hematopoietic stem cell transplantation in the elderly. Crit Rev Oncol Hematol. 2007 Oct;64(1):49–63. PubMed PMID: 17303434; eng
   PubMed Web of Science ®Google Scholar
• Holmes HM, Des Bordes JK, Kebriaei P, et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. 2014 Oct 01;5(4):422–430. PubMed PMID: 24835889; PubMed Central PMCID: PMC4232495. eng.
   PubMed Web of Science ®Google Scholar
• de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017 Mar 30;129(13):1753–1762. PubMed PMID: 28096091; PubMed Central PMCID: PMC5524528. eng.
   PubMed Web of Science ®Google Scholar
• Finelli C, Follo MY, Stanzani M, et al. Clinical impact of hypomethylating agents in the treatment of myelodysplastic syndromes. Curr Pharm Des. 2016;22(16):2349–2357. PubMed PMID: 26960675; eng.
   PubMed Web of Science ®Google Scholar
• Voso MT, Breccia M, Lunghi M, et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol. 2013 Apr;90(4):345–348. PubMed PMID: 23336938; eng.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419–425. PubMed PMID: 16609072; eng
   PubMed Web of Science ®Google Scholar
• Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 Jul;98(7):1067–1072. PubMed PMID: 23585522; PubMed Central PMCID: PMC3696610. eng.
   PubMed Web of Science ®Google Scholar
• Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome–a systematic review and meta-analysis. Haematologica. 2010 Feb;95(2):303–310. PubMed PMID: 19773261; PubMed Central PMCID: PMC2817034. eng.
   PubMed Web of Science ®Google Scholar
• Salim O, Toptas T, Avsar E, et al. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. Leuk Res. 2016 Jun;45:82–89. PubMed PMID: 27107658; eng.
   PubMedGoogle Scholar
• Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009 Feb 15;115(4):706–715. PubMed PMID: 19152429; eng.
   PubMed Web of Science ®Google Scholar
• Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008 Jul;87(7):527–536. PubMed PMID: 18351340; eng.
   PubMed Web of Science ®Google Scholar
• Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008 Jan 15;111(2):574–582. PubMed PMID: 17940203; eng.
   PubMed Web of Science ®Google Scholar
• Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008 Jul 20;26(21):3607–3613. PubMed PMID: 18559873; eng.
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549–557. PubMed PMID: 15703420; eng
   PubMed Web of Science ®Google Scholar
• Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011 Oct 6;118(14):3765–3776. PubMed PMID: 21753188; eng.
   PubMed Web of Science ®Google Scholar
• Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011 May 20;29(15):1971–1979. PubMed PMID: 21519010; eng.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013 Oct 24;122(17):2943–2964. PubMed PMID: 23980065; PubMed Central PMCID: PMC3811170. eng.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jan;15(1):60–87. PubMed PMID: 28040720; eng.
   PubMed Web of Science ®Google Scholar
• List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012 Jun 10;30(17):2134–2139. PubMed PMID: 22547607; eng.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010 Sep;34(9):1143–1150. PubMed PMID: 20451251; eng
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, Komrokji R Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opin Emerg Drugs. 2016 Sep;21(3):283–300. PubMed PMID: 27486848; eng.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Rezvani K The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol. 2008 Jan;45(1):39–48. PubMed PMID: 18179968; eng
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun;28(6):1280–1288. PubMed PMID: 24270737; PubMed Central PMCID: PMC4032802. eng.
   PubMed Web of Science ®Google Scholar
• Orskov AD, Treppendahl MB, Skovbo A, et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget. 2015 Apr 20;6(11):9612–9626. PubMed PMID: 25823822; PubMed Central PMCID: PMC4496243. eng.
   PubMed Web of Science ®Google Scholar
• Issa JJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1099–1110. PubMed PMID: 26296954; PubMed Central PMCID: PMC5557041. eng.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Scott BL, Boyd T, et al. Oral Azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Oncologist. 2015 Dec;20(12):1404–1412. PubMed PMID: 26463870; PubMed Central PMCID: PMC4679081. eng.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Gore SD, Kambhampati S, et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889–896. PubMed PMID: 26442612; PubMed Central PMCID: PMC4832070. eng.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Educ Program. 2013;2013:511–521. PubMed PMID: 24319226; eng.
   PubMedGoogle Scholar
• Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec 13;120(25):4945–4951. PubMed PMID: 22915641; PubMed Central PMCID: PMC3525020. eng.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Germing U Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison? Leukemia. 2013 Sep;27(9):1813–1819. PubMed PMID: 23644421; eng.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Daver N, Jabbour E, et al. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan;2(1):e12–e20. PubMed PMID: 26687423; PubMed Central PMCID: PMC4936479. eng.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Padron E, Yu D, et al. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug;89(8):809–812. PubMed PMID: 24764152; PubMed Central PMCID: PMC4561860. eng.
   PubMed Web of Science ®Google Scholar
• Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014 Apr;20(4):408–414. PubMed PMID: 24658078; eng.
   PubMed Web of Science ®Google Scholar
• Raje N, Vallet S Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010 Oct;12(5):586–597. PubMed PMID: 20886391; eng.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017 Oct;18(10):1338–1347. PubMed PMID: 28870615; eng
   PubMed Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537–545. PubMed PMID: 23169778; eng.
   PubMed Web of Science ®Google Scholar
• Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818–1825. PubMed PMID: 24345753; PubMed Central PMCID: PMC3962161. eng.
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014 Jun 15;120(12):1838–1846. PubMed PMID: 24706489; PubMed Central PMCID: PMC4298760. eng.
   PubMed Web of Science ®Google Scholar
• Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017 Mar;4(3):e127–e136. PubMed PMID: 28162984; eng.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr;17(4):496–508. PubMed PMID: 26968357; eng
   PubMed Web of Science ®Google Scholar
• Scharenberg C, Giai V, Pellagatti A, et al. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica. 2017 Mar;102(3):498–508. PubMed PMID: 27884971; PubMed Central PMCID: PMC5394951. eng.
   PubMed Web of Science ®Google Scholar
• Braulke F, Schulz X, Germing U, et al. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Ann Hematol. 2017 Jun;96(6):887–894. PubMed PMID: 28374162; eng.
   PubMed Web of Science ®Google Scholar
• Armstrong RN, Steeples V, Singh S, et al. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches. Adv Biol Regul. 2017 Sep 22. DOI:10.1016/j.jbior.2017.09.008. PubMed PMID: 28986033; eng.
   PubMedGoogle Scholar
• Pellagatti A, Boultwood J Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. Adv Biol Regul. 2017 Jan;63:59–70. PubMed PMID: 27639445; eng.
   PubMedGoogle Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016 Nov 24;375(21):2023–2036. PubMed PMID: 27959731; PubMed Central PMCID: PMC5217532. eng.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Ihorst G, Sander PN, et al. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2ʹ-deoxycytidine (Decitabine). Br J Haematol. 2017 Feb;176(4):609–617. PubMed PMID: 27905102; eng.
   PubMed Web of Science ®Google Scholar
• Miltiades P, Lamprianidou E, Vassilakopoulos TP, et al. The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with azacitidine. Clin Cancer Res. 2016 Apr 15;22(8):1958–1968. PubMed PMID: 26700206; eng
   PubMed Web of Science ®Google Scholar
• Follo MY, Marmiroli S, Faenza I, et al. Nuclear phospholipase C beta1 signaling, epigenetics and treatments in MDS. Adv Biol Regul. 2013 Jan;53(1):2–7. PubMed PMID: 23058275; eng.
   PubMedGoogle Scholar
• Follo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA. 2009 Sep 29;106(39):16811–16816. PubMed PMID: 19805378; PubMed Central PMCID: PMC2741479. eng.
   PubMed Web of Science ®Google Scholar
• Follo MY, Faenza I, Piazzi M, et al. Nuclear PI-PLCbeta1: an appraisal on targets and pathology. Adv Biol Regul. 2014 Jan;54:2–11. PubMed PMID: 24296032; eng.
   PubMedGoogle Scholar
• Fili C, Malagola M, Follo MY, et al. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res. 2013 Jun 15;19(12):3297–3308. PubMed PMID: 23596104; eng
   PubMed Web of Science ®Google Scholar
• Follo MY, Russo D, Finelli C, et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia. 2012 May;26(5):943–950. PubMed PMID: 22033492; eng.
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Mongiorgi S, et al. Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia. 2011 Feb;25(2):271–280. PubMed PMID: 21109771; eng.
   PubMed Web of Science ®Google Scholar
• Ramazzotti G, Faenza I, Fiume R, et al. PLC-beta1 and cell differentiation: an insight into myogenesis and osteogenesis. Adv Biol Regul. 2017 Jan;63:1–5. PubMed PMID: 27776973; eng
   PubMedGoogle Scholar
• Scarlata S, Singla A, Garwain O Phospholipase Cbeta interacts with cytosolic partners to regulate cell proliferation. Adv Biol Regul. 2017 Sep 09. DOI:10.1016/j.jbior.2017.09.004. PubMed PMID: 28919329; eng.
   PubMedGoogle Scholar
• Ratti S, Mongiorgi S, Ramazzotti G, et al. Nuclear inositide signaling via phospholipase C. J Cell Biochem. 2017 Aug;118(8):1969–1978. PubMed PMID: 28106288; eng.
   PubMed Web of Science ®Google Scholar
• Ramazzotti G, Faenza I, Fiume R, et al. The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol. 2011 Jan;226(1):14–20. PubMed PMID: 20658523; eng.
   PubMed Web of Science ®Google Scholar
• Follo MY, Mongiorgi S, Finelli C, et al. Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem. 2010 Apr 15;109(6):1065–1071. PubMed PMID: 20058233; eng.
   PubMed Web of Science ®Google Scholar
• Faenza I, Billi AM, Follo MY, et al. Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. Anticancer Res. 2005 May-Jun;25(3B):2039–2041. PubMed PMID: 16158942; eng.
   PubMed Web of Science ®Google Scholar
• Cocco L, Martelli AM, Gilmour RS Inositol lipid cycle in the nucleus. Cell Signal. 1994 Jul;6(5):481–485. PubMed PMID: 7818983; eng.
   PubMed Web of Science ®Google Scholar
• Cocco L, Follo MY, Manzoli L, et al. Phosphoinositide-specific phospholipase C in health and disease. J Lipid Res. 2015 Oct;56(10):1853–1860. PubMed PMID: 25821234; PubMed Central PMCID: PMC4583093. eng.
   PubMed Web of Science ®Google Scholar
• Follo MY, Manzoli L, Poli A, et al. PLC and PI3K/Akt/mTOR signalling in disease and cancer. Adv Biol Regul. 2015 Jan;57:10–16. PubMed PMID: 25482988; eng
   PubMedGoogle Scholar
• Cocco L, Manzoli L, Faenza I, et al. Modulation of nuclear PI-PLCbeta1 during cell differentiation. Adv Biol Regul. 2016 Jan;60:1–5. PubMed PMID: 26525203; eng.
   PubMedGoogle Scholar
• Mongiorgi S, Finelli C, Yang YR, et al. Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. Expert Opin Ther Targets. 2016 Jun;20(6):677–687. PubMed PMID: 26610046; eng.
   PubMed Web of Science ®Google Scholar
• Mongiorgi S, Follo MY, Yang YR, et al. Selective activation of nuclear PI-PLCbeta1 during normal and therapy-related differentiation. Curr Pharm Des. 2016;22(16):2345–2348. PubMed PMID: 26916022; eng.
   PubMed Web of Science ®Google Scholar
• Manzoli L, Mongiorgi S, Clissa C, et al. Role of nuclear inositide signalling in myelodysplastic syndromes therapy. Mini Rev Med Chem. 2014;14(11):873-883. PubMed PMID: 25307310; eng.
   PubMed Web of Science ®Google Scholar
• Follo MY, Mongiorgi S, Clissa C, et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia. 2012 Dec;26(12):2474–2482. PubMed PMID: 22596089; eng.
   PubMed Web of Science ®Google Scholar
• Cocco L, Finelli C, Mongiorgi S, et al. An increased expression of PI-PLCbeta1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. J Leukoc Biol. 2015 Nov;98(5):769–780. PubMed PMID: 25977289; eng.
   PubMed Web of Science ®Google Scholar
• Bejar R Implications of molecular genetic diversity in myelodysplastic syndromes. Curr Opin Hematol. 2017 Mar;24(2):73–78 PubMed PMID: 27875374; PubMed Central PMCID: PMC5433846. eng.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Dolatshad H, Bh Y, et al. Application of genome editing technologies to the study and treatment of hematological disease. Adv Biol Regul. 2016 Jan;60:122–134. PubMed PMID: 26433620; eng.
   PubMedGoogle Scholar
• Janusz K, Del Rey M, Abaigar M, et al. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. Leuk Res. 2017 May;56:82–87. PubMed PMID: 28222336; eng
   PubMed Web of Science ®Google Scholar
• Cremers EM, Westers TM, Alhan C, et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica. 2017 Feb;102(2):320–326. PubMed PMID: 27658438; PubMed Central PMCID: PMC5286939. eng.
   PubMed Web of Science ®Google Scholar
• Zuo Z, Maiti S, Hu S, et al. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol. 2015 Mar;28(3):373–382. PubMed PMID: 25216221; eng.
   PubMed Web of Science ®Google Scholar
• Guo Y, Strickland SA, Mohan S, et al. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. Leuk Lymphoma. 2017 Sep;58(9):1–15. PubMed PMID: 28084850; PubMed Central PMCID: PMC5505168. eng.
   Web of Science ®Google Scholar
• Wen J, Huang Y, Li H, et al. Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome. Int J Hematol. 2017 Jun;105(6):777–783. PubMed PMID: 28224273; eng.
   PubMed Web of Science ®Google Scholar
• Choi JS, Nam MH, Yoon SY, et al. MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes. Leuk Res. 2015 Jul;39(7):763–768. PubMed PMID: 25975751; eng.
   PubMed Web of Science ®Google Scholar